Somatostatin Injection 3 Mg

Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of somatostatin injection 3 mg in China. Welcome to wholesale bulk high quality somatostatin injection 3 mg for sale here from our factory. Good service and reasonable price are available.

Somatostatin Injection 3 mg is an artificially synthesized cyclic tetrapeptide drug with a chemical structure identical to natural somatostatin. It exerts a wide range of clinical therapeutic effects by inhibiting the secretion of various hormones and regulating visceral blood flow. Its main component is somatostatin acetate (artificially synthesized), with a molecular formula of C76H104N18O19S2, a molecular weight of 1638.89, and a white or off white freeze-dried block or powder appearance. It needs to be dissolved in physiological saline or 5% glucose solution before use.

Somatostatin COA

Certificate of Analysis
Compound name	Somatostatin
Grade	Pharmaceutical grade
CAS No.	51110-01-1
Quantity	10g
Packaging standard	PE bag+Al foil bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202601090056
MFG	Jan 9th 2026
EXP	Jan 8th 2029
Structure
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.48%
Loss on drying	≤1.0%	0.34%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.0%	99.90%
Single impurity	<0.8%	0.56%
Total microbial count	≤750cfu/g	170
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	400ppm
Storage	Store in a sealed, dark, and dry place below -20°C

Somatostatin Injection 3 Mg is an endogenous regulatory peptide widely present in tissues such as the central nervous system, hypothalamus, pancreas, and gastrointestinal mucosa. Its natural forms are mainly 14 peptide (SS-14) and 28 peptide (SS-28). The injectable somatostatin commonly used in clinical practice is a synthetic 14 peptide with a structure identical to endogenous somatostatin. It has the characteristics of short half-life, wide range of effects, and high safety, and mainly exerts pharmacological effects through continuous intravenous infusion.

Widely inhibiting the release of endocrine hormones such as somatostatin can suppress the secretion of growth hormone (GH) and thyroid stimulating hormone (TSH) in the anterior pituitary gland; Inhibit the secretion of glucagon by pancreatic alpha cells and insulin by pancreatic beta cells; Inhibit the secretion of various hormones such as gastrin by gastrointestinal G cells, 5-hydroxytryptamine, and vasoactive intestinal peptide (VIP) by intestinal chromaffin cells. Through multi-target inhibition, achieve overall regulation of the body's metabolism, digestion, and circulatory systems.

Strong inhibition of exocrine secretion of digestive glands significantly suppresses the secretion of gastric acid, pepsin, pancreatic juice (water, bicarbonate, digestive enzymes), bile, and small intestinal fluid, reduces the total amount of digestive fluid, lowers the pressure inside the digestive tract, and alleviates mucosal irritation and self digestion damage.

Regulating visceral hemodynamics to selectively constrict visceral blood vessels, reduce portal vein pressure, and decrease portal vein blood flow, with minimal impact on systemic hemodynamics, is an important mechanism for treating portal hypertension related bleeding.
Inhibiting gastrointestinal peristalsis and protecting mucosal barriers slows down gastrointestinal transport speed, reducing mechanical stimulation of bleeding wounds or postoperative anastomotic sites caused by gastrointestinal movement; Inhibit the release of inflammatory factors, alleviate tissue edema, maintain intestinal mucosal barrier function, and reduce bacterial translocation.

Regulating cell proliferation and immune function has inhibitory effects on proliferation and induces apoptosis in various endocrine and gastrointestinal tumor cells. At the same time, it can moderately regulate immune inflammatory responses and alleviate systemic inflammatory response syndrome (SIRS).

Pharmacokinetic characteristics

Rapid distribution after intravenous injection, with a plasma half-life of only 1.1-3 minutes, requires continuous intravenous infusion to maintain stable blood drug concentration. Mainly metabolized in the liver and kidneys, excreted through urine without significant accumulation, suitable for short-term use in critically ill patients.
 

Reference information source:
The National Pharmacopoeia Committee's "Clinical Medication Guidelines for the Pharmacopoeia of the People's Republic of China - Chemical and Biological Products Volume" (2020 edition)
Guyton & Hall, Textbook of Medical Physiology, 14th Edition, Elsevier, 2020
Pancreatic Disease Group of the Digestive Disease Branch of the Chinese Medical Association, "Guidelines for the Diagnosis and Treatment of Acute pancreatitis in China (2021)"

Esophageal and gastric variceal rupture and bleeding

 

Esophageal and gastric variceal bleeding caused by portal hypertension in cirrhosis is a clinical emergency with a high mortality rate. Somatostatin Injection 3 Mg is a first-line hemostatic drug recommended by domestic and international guidelines, which can quickly reduce portal vein pressure and control acute bleeding.

Its mechanism of action includes: constriction of visceral blood vessels, reduction of portal vein blood flow, and reduction of pressure in varicose veins; Inhibit gastric acid and gastrin secretion, increase gastric pH, and stabilize blood clots; Reduce the risk of rebleeding. Continuous intravenous infusion after loading dose is commonly used in clinical practice, and combined with endoscopic treatment, it can significantly improve the success rate of hemostasis.

nonvariceal upper gastrointestinal bleeding

 

Major bleeding caused by gastric ulcers, duodenal ulcers, acute erosive hemorrhagic gastritis, stress ulcers, etc. Somatostatin inhibits gastric acid secretion, reduces gastric mucosal blood flow, alleviates wound bleeding, and assists proton pump inhibitors (PPIs) and endoscopic hemostasis. It is particularly suitable for high-risk rebleeding patients and critically ill cases that cannot be immediately treated with endoscopy.

Reference information source:

Chinese Medical Association Hepatology Branch, Digestive Disease Branch, Endoscopy Branch, "Guidelines for Prevention and Treatment of Esophageal and Gastric Varicocele Bleeding in Cirrhotic Portal Hypertension (2022)"
British Society of Gastroenterology (BSG), Guidelines for the management of acute upper gastrointestinal bleeding, 2021
American College of Gastroenterology (ACG), Management of Acute Gastrointestinal Bleeding from Ulcers, 2023
National Medical Products Administration Drug Evaluation Center, "Technical Guidelines for Clinical Trials of Somatostatin for Injection"

Acute pancreatitis

 

The core pathological mechanism of acute pancreatitis is abnormal activation of pancreatic enzymes leading to self digestion of the pancreas and systemic inflammatory response. Somatostatin can effectively inhibit pancreatic exocrine secretion, reduce pancreatic enzyme synthesis and release, block the cascade reaction of pancreatic enzyme activation, alleviate pancreatic edema, necrosis, and systemic inflammatory response.

Mild acute pancreatitis can alleviate symptoms and shorten the course of the disease; For severe acute pancreatitis, it can reduce the incidence of multiple organ failure, reduce complications such as abdominal hypertension, pancreatic fistula, and infection, and is recommended as a basic treatment drug in domestic and foreign pancreatitis guidelines.

Prevention of perioperative complications in pancreatic surgery

 

The use of somatostatin during the perioperative period of pancreaticoduodenectomy, distal pancreatectomy, and pancreatic trauma repair can significantly reduce the incidence of postoperative complications such as pancreatic fistula, abdominal bleeding, infection, and acute pancreatitis, shorten hospitalization time, and improve surgical safety.

Adjuvant treatment of pancreatic fistula

 

For postoperative or traumatic pancreatic fistula, somatostatin can reduce pancreatic secretion, decrease fistula fluid flow, promote fistula closure, and is often used in combination with drainage and nutritional support.

Reference information source:
Pancreatic Disease Group of the Digestive Disease Branch of the Chinese Medical Association, "Guidelines for the Diagnosis and Treatment of Acute pancreatitis in China (2021)"
Expert Consensus on Prevention and Treatment of Postoperative Surgical Complications in Pancreatic Surgery (2022), Pancreatic Surgery Group, Chinese Medical Association Surgery Branch
Working Group of the International Association of Pancreatology (IAP), IAP/APA evidence-based guidelines for the management of acute pancreatitis, 2022
Editorial Board of Chinese Journal of Surgery, "Diagnosis and Treatment Guidelines for Pancreatic Fistula in China (2020 Edition)"

Adjuvant treatment for pancreatic fistula, biliary fistula, and intestinal fistula

 

Somatostatin inhibits exocrine secretion from the pancreas, biliary tract, and intestine, reduces the amount of fluid discharged from fistulas, decreases the corrosion of surrounding tissues by digestive enzymes, alleviates local inflammation, and promotes fistula closure. Clinically, it is commonly used in the conservative treatment stage, combined with fasting, gastrointestinal decompression, parenteral nutrition, and anti infective therapy.

Acute adhesive intestinal obstruction

 

For simple and incomplete adhesive intestinal obstruction, somatostatin can reduce gastrointestinal secretion, alleviate intestinal wall edema, lower intestinal lumen pressure, relieve abdominal distension and pain, promote intestinal function recovery, and reduce the need for surgical intervention.

Reference information source:
Gastrointestinal Surgery Group of the Chinese Medical Association Surgery Branch, "Chinese Guidelines for the Diagnosis and Treatment of Intestinal Obstruction (2021)"
Editorial Board of Chinese Journal of Practical Surgery, Expert Consensus on Fistula Treatment in Abdominal Surgery (2019)
World Society of Emergency Surgery (WSES), Guidelines for the management of small bowel obstruction, 2022
Editorial Board of the Chinese Journal of Digestive Surgery, Expert Consensus on Diagnosis and Treatment of Gallbladder Fistula (2020)

Diabetes ketoacidosis (DKA)

 

The core pathological mechanism of DKA is insulin deficiency and excessive activation of glucocorticoids. Somatostatin Injection 3 Mg can inhibit the secretion of glucocorticoids such as glucagon, growth hormone, and cortisol, reduce hepatic glucose output and fat breakdown, lower ketone body production, assist insulin in rapidly correcting ketosis, stabilizing blood sugar, reducing insulin dosage, and lowering the risk of hypoglycemia.

Acromegaly

 

Somatostatin can inhibit excessive secretion of pituitary growth hormone and is used for short-term control, preoperative preparation, or symptom relief in patients with acromegaly who are unable to undergo surgery. Long acting somatostatin analogs (such as octreotide and lanreotide) are also commonly used in clinical practice for long-term treatment.

Reference information source:
American Diabetes Association (ADA), Standards of Medical Care in Diabetes, 2024
Endocrinology Branch of Chinese Medical Association, Guidelines for Diagnosis and Treatment of Type 1 diabetes in China (2023)
Endocrine Society, Clinical Practice Guideline for Acromegaly, 2021
Editorial Board of the Chinese Journal of Endocrinology and Metabolism, "Expert Consensus on the Diagnosis and Treatment of Acromegaly in China (2020)"

Hot Tags: somatostatin injection 3 mg, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale